Abstract: Provided herein are combinations of compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Abstract: The present invention provides a nitroreductase-releasable pro-drug of the formula: where Ar1, m, n, Z, Y, L, and A are as defined herein, and methods for using and producing the same. Compound of formula I is useful in oral administration of the active pharmaceutical ingredient to the distal gut region of a subject to treat a wide variety of clinical conditions associated with distal gut region of a subject, such as colorectal cancer, inflammatory bowel disease (IBD), infectious diarrhea, bacterial infections, and bacterial overgrowth.

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

Abstract: The present invention provides a therapeutic combination for use in treating an infection with a pathogen. The therapeutic combination comprises an aminoglycoside antibiotic; and a nucleic acid monoalkylating agent that substitutes a single nucleotide of a nucleic acid with an alkyl group, wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said aminoglycoside antibiotic; or wherein the therapeutic combination provides an enhanced suppression of a pathogen when compared with an otherwise identical composition lacking said nucleic acid monoalkylating agent; and kits for performing said method.

Abstract: An object is to provide a Th1-increasing agent that can reduce constraints on storage conditions and feeding form and sufficiently increase Th1 at lower doses. A Th1-increasing agent containing a cellulose derivative as an active ingredient, the cellulose derivative having a degree of butyryl substitution of 0.3 or greater and 2.6 or less, and a total degree of substitution of 0.5 or greater and 2.8 or less.

Abstract: The present disclosure is directed to novel glycoside derivatives of terpenes, particularly derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising 2?-O-acetylated ribose, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.

Abstract: Truncated triterpene saponin analogues containing a trisaccharide or tetrasaccharide ester are disclosed. Also disclosed are pharmaceutical compositions comprising truncated saponin analogues and synthetic methods of producing the truncated saponin analogues. Another aspect of the present application relates to a method for immunizing a subject, comprising administering to the subject the pharmaceutical composition comprising a minimal saponin analogue and an antigen.

Abstract: The invention provides compounds, compositions and methods for treating medical disorders, such as cancer, an autoimmune disorder, and/or a neurological disorder, and inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase using a compound according to Formula I or a pharmaceutically acceptable salt thereof, or a related compound provided herein.

Abstract: The present invention relates to soluble concentrate compositions useful in agriculture to control pests harmful to commercial crops, including ornamental plants, comprising (i) abamectin; (ii) polyoxyethylene (20) sorbitan monolaurate; (iii) polyoxyethylene (20) sorbitan monooleate; wherein the weight ratio of polyoxyethylene (20) sorbitan monolaurate to polyoxyethylene (20) sorbitan monooleate is from 1:2.5 to 15:1.

Abstract: The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof are provided. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.

Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.

Abstract: Disclosed herein are oligosaccharides and intermediates useful for the production thereof. The compounds are useful as analytical standards and as intermediates for the preparation of more complex oligosaccharide and N-glycan products. The compounds may be prepared in high purity using the selective stop/go synthetic methods disclosed herein.

Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Abstract: The present disclosure relates to novel methods for preparing antibacterial aminoglycoside compounds and the compounds used in such preparations.

Abstract: The disclosure discloses a glyco-metal-organic frameworks-based hepatic targeted therapeutic drug and a preparation method thereof, and belongs to the field of biomedicine. The disclosure loads a chemotherapeutic drug onto specific metal-organic frameworks, and modifies targeted molecule galactose on the surface of the materials through amide reaction. The biocompatibility and cytotoxicity of the obtained hepatic targeted therapeutic drug have been carefully evaluated at the cellular level. The hepatic targeted therapeutic drug of the disclosure has good stability and acidic pH triggered drug release property, and can exert the synergistic therapeutic effect of photodynamic therapy and chemotherapy. In addition, in vivo behavioral tracing and therapeutic efficacy are evaluated in mouse models with subcutaneous solid tumor and tumor in situ, and the disclosure is expected to play a huge role in clinical applications.

Abstract: High-purity hydrous D-allose crystals and a method of efficiently obtaining the crystals are provided. To a D-allose-containing solution having a purity of D-allose of at least 80% (g/g) in a solute, in a metastable region in a supersaturated state of 30° C. or less, D-allose seed crystals are added. Then, the temperature of the solution is lowered by 10° C. or more for cooling and crystallization to initially obtain “hydrous D-allose crystals”, and the crystallization water thereof is removed in a specified temperature zone to obtain novel “anhydrous D-allose crystals”.

Abstract: Embodiments of the present application relate to functionalized N-acetylgalactosamine analogs, methods of making, and uses of the same. In particular, polyvalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety of linkers containing functional groups. These functionalized N-acetylgalactosamine analogs may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.